Emmaus Life Sciences Inc EMMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EMMA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.11
- Day Range
- $0.11–0.11
- 52-Week Range
- $0.05–0.34
- Bid/Ask
- $0.02 / $0.16
- Market Cap
- $6.10 Mil
- Volume/Avg
- 291 / 18,124
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 55
- Website
- https://www.emmausmedical.com
Valuation
Metric
|
EMMA
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.21 |
Price/Cash Flow | — |
Price/Earnings
EMMA
Financial Strength
Metric
|
EMMA
|
---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.15 |
Interest Coverage | 0.20 |
Quick Ratio
EMMA
Profitability
Metric
|
EMMA
|
---|---|
Return on Assets (Normalized) | −11.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
EMMA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ctgnhhkpc | Nsfjv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tcpmhsrv | Wkvcbq | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fxnrvlsn | Mjvnzg | $98.9 Bil | |
MRNA
| Moderna Inc | Nlhgvhxrc | Jrkw | $39.7 Bil | |
ARGX
| argenx SE ADR | Kljfndb | Nrftz | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Yfmqylgd | Bss | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ncgpjdvg | Jsgswm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zkwfshtky | Zygvt | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gkmrchtl | Qxjkjhp | $12.3 Bil | |
INCY
| Incyte Corp | Cmbxypvr | Tmjwmq | $11.8 Bil |